MCMI SPV Holdco

MCMI SPV Holdco is a strategic holding company and special purpose vehicle managed by Medicxi, a leading life sciences venture capital firm. The entity was primarily established to facilitate the roll-up and merger of several asset-centric biotechnology companies into Centessa Pharmaceuticals in 2021. By consolidating diverse programs—such as those from Orexia Therapeutics, Palladio Biosciences, and Z Factor—MCMI SPV Holdco created a unified platform for developing high-conviction therapeutic assets. The company embodies the 'asset-centric' investment model, focusing on efficient clinical development across multiple therapeutic areas including neurology, hematology, and nephrology. While the underlying assets now operate under the Centessa umbrella, MCMI SPV Holdco remains a significant structural component of the initial formation and financing strategy. This model allows for the aggregation of specialized expertise and resources to advance a broad pipeline of clinical-stage candidates.